Potential of the Technology
Potential of the Technology
- Early responses against viruses with no available vaccines or cure methods
- emerging viruses, mutant viruses, incoming foreign viruses and etc. - Treatment of rare viruses occurring locally or regionally
- The innovative mini-antibody has demonstrated broad antiviral activities regardless of genome types, showing enormous potential to be a blockbuster drug that could exceed Oseltamivir (brand name Tamiflu), the mostly known NA(Neuraminidase)-inhibitor antiviral drug (USD 15.5 billion/year)
-
Various prescriptions or treatments such as therapeutic agent, vaccine adjuvant, and substitute medicine are applicable.
1) Single prescription
2) Compound prescription in combination with generic NA inhibitors (Oseltamivir)
3) Treatment of patients infected with NA-inhibitor-resistant viruses
4) Treatment of patients infected with severe influenza viruses after vaccination
5) Prevention of flu infection - Novelgen's therapeutic antibody provides the ability to overcome the fundamental limitations, such as drug resistance, of present therapeutic protocols against viral infections and to manage high-> risk viruses transferable unexpectedly to humans - Opportunity for market expansion.
- Novelgen's innovative technological platform for antibody engineering provides the ability to develop novel therapeutic agents against various viral diseases - Zika, MERS, Tick-borne diseases, Severe Fever Thrombocytopenia Syndrome, Epidemic hemorrhagic fever(Hantavirus), and etc.
